Yahoo Finance5d
Imbed Biosciences Announces FDA IDE Approval for Silver-Gallium Synthetic Antimicrobial Matrix Clinical Study with Human Donor Site Wounds
March 11, 2025--(BUSINESS WIRE)--Imbed Biosciences ("Imbed"), a pioneer in breakthrough wound care synthetic matrix technology, today announced the U.S. Food and Drug Administration (FDA ...
Morningstar5d
Imbed Biosciences Announces FDA IDE Approval for Silver-Gallium Synthetic Antimicrobial Matrix Clinical Study with Human Donor Site Wounds
Investigational Device Exemption (IDE) enables Imbed’s Silver-Gallium, Ultra-Thin Matrix Technology to ... today announced the U.S. Food and Drug Administration (FDA) has approved an ...